Gan & Lee Pharmaceuticals Co Ltd (603087 SHG) stock market data APIs
¥56.1429
1.48(2.6%)
as of June 5, 2025
Try our APIs with
free plan!
Gan & Lee Pharmaceuticals Co Ltd Financial Data Overview
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company's products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Prev. Close
56.1429
Open
57.6198
High
57.548
Low
56.0145
52 wk Range
37.63-57.94
Market Cap
33 918 M
P/E Ratio
40.0213
Shares Outstanding
601 M
Revenue
3 470 M
EPS
0.19
Beta
1.612
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gan & Lee Pharmaceuticals Co Ltd data using free add-ons & libraries
Get Gan & Lee Pharmaceuticals Co Ltd Fundamental Data
{
"General": {
"Code": "603087",
"Type": "Common Stock",
"Name": "Gan & Lee Pharmaceuticals Co Ltd",
"Exchange": "SHG",
"CurrencyCode": "CNY",
"CurrencyName": "Renminbi",
"CurrencySymbol": "\u00a5",
"CountryName": "China",
"CountryISO": "CN",
"OpenFigi": null,
"ISIN": "CNE100003ZH1",
"CIK": null,
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": null,
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Medical Instruments & Supplies",
"Description": "Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company's products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro ..."
}
}Gan & Lee Pharmaceuticals Co Ltd Fundamental data includes:
- Net Revenue: 3 470 M
- EBITDA: 772 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gan & Lee Pharmaceuticals Co Ltd News
New
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in...
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration ("...
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile support...
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
